select a format

Single User License
USD 2000 INR 129580
Site License
USD 4000 INR 259160
Corporate User License
USD 6000 INR 388740

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Osteoarthritis Pain-Pipeline Review, H2 2015

Osteoarthritis Pain-Pipeline Review, H2 2015


  • Products Id :- GMDHC7221IDB
  • |
  • Pages: 190
  • |
  • October 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Osteoarthritis Pain-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Osteoarthritis Pain-Pipeline Review, H2 2015', provides an overview of the Osteoarthritis Pain's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Osteoarthritis Pain and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Osteoarthritis Pain pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Osteoarthritis Pain

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Osteoarthritis Pain pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Osteoarthritis Pain Overview 8

Therapeutics Development 9

Pipeline Products for Osteoarthritis Pain-Overview 9

Pipeline Products for Osteoarthritis Pain-Comparative Analysis 10

Osteoarthritis Pain-Therapeutics under Development by Companies 11

Osteoarthritis Pain-Therapeutics under Investigation by Universities/Institutes 15

Osteoarthritis Pain-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Unknown Stage Products 19

Osteoarthritis Pain-Products under Development by Companies 20

Osteoarthritis Pain-Products under Investigation by Universities/Institutes 24

Osteoarthritis Pain-Companies Involved in Therapeutics Development 25

AbbVie Inc. 25

Addex Therapeutics Ltd 26

Afferent Pharmaceuticals, Inc. 27

Akron Molecules AG 28

Allergan Plc 29

Amgen Inc. 30

Ampio Pharmaceuticals, Inc. 31

AnaMar AB 32

Antibe Therapeutics, Inc. 33

AskAt Inc. 34

Astellas Pharma Inc. 35

AstraZeneca Plc 36

Boehringer Ingelheim GmbH 37

Bone Medical Limited 38

Centrexion Corporation 39

Convergence Pharmaceuticals Ltd. 40

Eli Lilly and Company 41

Elite Pharmaceuticals, Inc. 42

Flexion Therapeutics, Inc. 43

Grunenthal GmbH 44

Iroko Pharmaceuticals, LLC 45

Nektar Therapeutics 46

Nuvo Research Inc. 47

Pfizer Inc. 48

Phosphagenics Limited 49

Pozen, Inc. 50

Purdue Pharma L.P. 51

Regeneron Pharmaceuticals, Inc. 52

Rottapharm SpA 53

Osteoarthritis Pain-Therapeutics Assessment 54

Assessment by Monotherapy Products 54

Assessment by Combination Products 55

Assessment by Target 56

Assessment by Mechanism of Action 59

Assessment by Route of Administration 62

Assessment by Molecule Type 64

Drug Profiles 66

(lidocaine hydrochloride + tetracaine hydrochloride)-Drug Profile 66

(naltrexone hydrochloride + oxycodone hydrochloride) SR-Drug Profile 68

A-889425-Drug Profile 70

AAT-008-Drug Profile 71

ADX-71441-Drug Profile 72

AF-219-Drug Profile 73

AKR-202-Drug Profile 75

AMAP-102-Drug Profile 76

Ampion-Drug Profile 78

AQU-010-Drug Profile 80

AS-288640100-Drug Profile 81

ATB-346-Drug Profile 82

BI-1026706-Drug Profile 84

calcitonin-Drug Profile 85

capsaicin-Drug Profile 87

cebranopadol-Drug Profile 89

celecoxib-Drug Profile 91

CGS-125-Drug Profile 92

CR-4056-Drug Profile 93

CRB-0022-Drug Profile 94

CRB-0089-Drug Profile 95

duloxetine hydrochloride DR-Drug Profile 96

ELS-130-Drug Profile 98

fasinumab-Drug Profile 99

fulranumab-Drug Profile 101

FX-005-Drug Profile 104

grapiprant-Drug Profile 105

ibuprofen-Drug Profile 107

MEDI-7352-Drug Profile 108

naproxen sodium-Drug Profile 109

NEO-5024-Drug Profile 111

NEO-6860-Drug Profile 112

NKTR-181-Drug Profile 113

OLT-1177-Drug Profile 115

onabotulinumtoxin A-Drug Profile 116

oxycodone ER-Drug Profile 119

PA-300 DR-Drug Profile 121

PA-65020-Drug Profile 122

Small Molecule to Agonize TRPV1 for Osteoarthritic Pain-Drug Profile 123

Small Molecule to Antagonize P2Y14 for Osteoarthritic Pain-Drug Profile 124

Small Molecules to Agonize TRPV1 for Osteoarthritis Pain-Drug Profile 125

Small Molecules to Block Calcium Ion Channel for Osteoarthritis Pain-Drug Profile 126

Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain-Drug Profile 127

Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation-Drug Profile 128

Small Molecules to Inhibit PDE2 for Osteoarthritis Pain-Drug Profile 129

tanezumab-Drug Profile 130

triamcinolone acetonide sodium phosphate SR-Drug Profile 133

V-116517-Drug Profile 135

VG-201-Drug Profile 136

VLNX-4975-Drug Profile 137

Osteoarthritis Pain-Recent Pipeline Updates 138

Osteoarthritis Pain-Dormant Projects 170

Osteoarthritis Pain-Discontinued Products 175

Osteoarthritis Pain-Product Development Milestones 177

Featured News & Press Releases 177

Appendix 185

Methodology 185

Coverage 185

Secondary Research 185

Primary Research 185

Expert Panel Validation 185

Contact Us 185

Disclaimer 186

List of Tables

Number of Products under Development for Osteoarthritis Pain, H2 2015 13

Number of Products under Development for Osteoarthritis Pain-Comparative Analysis, H2 2015 14

Number of Products under Development by Companies, H2 2015 16

Number of Products under Development by Companies, H2 2015 (Contd..1) 17

Number of Products under Development by Companies, H2 2015 (Contd..2) 18

Number of Products under Investigation by Universities/Institutes, H2 2015 19

Comparative Analysis by Late Stage Development, H2 2015 20

Comparative Analysis by Clinical Stage Development, H2 2015 21

Comparative Analysis by Early Stage Development, H2 2015 22

Comparative Analysis by Unknown Stage Development, H2 2015 23

Products under Development by Companies, H2 2015 24

Products under Development by Companies, H2 2015 (Contd..1) 25

Products under Development by Companies, H2 2015 (Contd..2) 26

Products under Development by Companies, H2 2015 (Contd..3) 27

Products under Investigation by Universities/Institutes, H2 2015 28

Osteoarthritis Pain-Pipeline by AbbVie Inc., H2 2015 29

Osteoarthritis Pain-Pipeline by Addex Therapeutics Ltd, H2 2015 30

Osteoarthritis Pain-Pipeline by Afferent Pharmaceuticals, Inc., H2 2015 31

Osteoarthritis Pain-Pipeline by Akron Molecules AG, H2 2015 32

Osteoarthritis Pain-Pipeline by Allergan Plc, H2 2015 33

Osteoarthritis Pain-Pipeline by Amgen Inc., H2 2015 34

Osteoarthritis Pain-Pipeline by Ampio Pharmaceuticals, Inc., H2 2015 35

Osteoarthritis Pain-Pipeline by AnaMar AB, H2 2015 36

Osteoarthritis Pain-Pipeline by Antibe Therapeutics, Inc., H2 2015 37

Osteoarthritis Pain-Pipeline by AskAt Inc., H2 2015 38

Osteoarthritis Pain-Pipeline by Astellas Pharma Inc., H2 2015 39

Osteoarthritis Pain-Pipeline by AstraZeneca Plc, H2 2015 40

Osteoarthritis Pain-Pipeline by Boehringer Ingelheim GmbH, H2 2015 41

Osteoarthritis Pain-Pipeline by Bone Medical Limited, H2 2015 42

Osteoarthritis Pain-Pipeline by Centrexion Corporation, H2 2015 43

Osteoarthritis Pain-Pipeline by Convergence Pharmaceuticals Ltd., H2 2015 44

Osteoarthritis Pain-Pipeline by Eli Lilly and Company, H2 2015 45

Osteoarthritis Pain-Pipeline by Elite Pharmaceuticals, Inc., H2 2015 46

Osteoarthritis Pain-Pipeline by Flexion Therapeutics, Inc., H2 2015 47

Osteoarthritis Pain-Pipeline by Grunenthal GmbH, H2 2015 48

Osteoarthritis Pain-Pipeline by Iroko Pharmaceuticals, LLC, H2 2015 49

Osteoarthritis Pain-Pipeline by Nektar Therapeutics, H2 2015 50

Osteoarthritis Pain-Pipeline by Nuvo Research Inc., H2 2015 51

Osteoarthritis Pain-Pipeline by Pfizer Inc., H2 2015 52

Osteoarthritis Pain-Pipeline by Phosphagenics Limited, H2 2015 53

Osteoarthritis Pain-Pipeline by Pozen, Inc., H2 2015 54

Osteoarthritis Pain-Pipeline by Purdue Pharma L.P., H2 2015 55

Osteoarthritis Pain-Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015 56

Osteoarthritis Pain-Pipeline by Rottapharm SpA, H2 2015 57

Assessment by Monotherapy Products, H2 2015 58

Assessment by Combination Products, H2 2015 59

Number of Products by Stage and Target, H2 2015 61

Number of Products by Stage and Mechanism of Action, H2 2015 64

Number of Products by Stage and Route of Administration, H2 2015 67

Number of Products by Stage and Molecule Type, H2 2015 69

Osteoarthritis Pain Therapeutics-Recent Pipeline Updates, H2 2015 142

Osteoarthritis Pain-Dormant Projects, H2 2015 174

Osteoarthritis Pain-Dormant Projects (Contd..1), H2 2015 175

Osteoarthritis Pain-Dormant Projects (Contd..2), H2 2015 176

Osteoarthritis Pain-Dormant Projects (Contd..3), H2 2015 177

Osteoarthritis Pain-Dormant Projects (Contd..4), H2 2015 178

Osteoarthritis Pain-Discontinued Products, H2 2015 179

Osteoarthritis Pain-Discontinued Products (Contd..1), H2 2015 180

List of Figures

Number of Products under Development for Osteoarthritis Pain, H2 2015 13

Number of Products under Development for Osteoarthritis Pain-Comparative Analysis, H2 2015 14

Number of Products under Development by Companies, H2 2015 15

Number of Products under Investigation by Universities/Institutes, H2 2015 19

Comparative Analysis by Clinical Stage Development, H2 2015 21

Comparative Analysis by Early Stage Products, H2 2015 22

Assessment by Monotherapy Products, H2 2015 58

Assessment by Combination Products, H2 2015 59

Number of Products by Top 10 Targets, H2 2015 60

Number of Products by Stage and Top 10 Targets, H2 2015 60

Number of Products by Top 10 Mechanism of Actions, H2 2015 63

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 63

Number of Products by Routes of Administration, H2 2015 66

Number of Products by Stage and Routes of Administration, H2 2015 66

Number of Products by Molecule Types, H2 2015 68

Number of Products by Stage and Molecule Types, H2 2015 68

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc.

Addex Therapeutics Ltd

Afferent Pharmaceuticals, Inc.

Akron Molecules AG

Allergan Plc

Amgen Inc.

Ampio Pharmaceuticals, Inc.

AnaMar AB

Antibe Therapeutics, Inc.

AskAt Inc.

Astellas Pharma Inc.

AstraZeneca Plc

Boehringer Ingelheim GmbH

Bone Medical Limited

Centrexion Corporation

Convergence Pharmaceuticals Ltd.

Eli Lilly and Company

Elite Pharmaceuticals, Inc.

Flexion Therapeutics, Inc.

Grunenthal GmbH

Iroko Pharmaceuticals, LLC

Nektar Therapeutics

Nuvo Research Inc.

Pfizer Inc.

Phosphagenics Limited

Pozen, Inc.

Purdue Pharma L.P.

Regeneron Pharmaceuticals, Inc.

Rottapharm SpA

Osteoarthritis Pain Therapeutic Products under Development, Key Players in Osteoarthritis Pain Therapeutics, Osteoarthritis Pain Pipeline Overview, Osteoarthritis Pain Pipeline, Osteoarthritis Pain Pipeline Assessment


Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com